Key considerations in expanding global manufacture of a commercialized CAR-T cell therapy

Following the successful commercial launch of CARVYKTI^®, partners Legend Biotech and Johnson & Johnson are busy expanding global production capabilities. Sarah Snykers, Head of Operations, Legend Biotech, took time out to talk to David McCall, Cell & Gene Therapy Insights about the ins and outs of setting up commercial CAR-T manufacturing facilities in Europe.

Please enter your email to access content Read now